Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) saw a significant decline in short interest in September. As of September 30th, there was short interest totaling 119,457 shares, a decline of 36.4% from the September 15th total of 187,942 shares. Approximately 6.6% of the company’s stock are short sold. Based on an average trading volume of 69,825 shares, the short-interest ratio is presently 1.7 days.
Wall Street Analyst Weigh In
Separately, Weiss Ratings upgraded shares of Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has an average rating of “Sell”.
Read Our Latest Report on APVO
Aptevo Therapeutics Price Performance
Shares of NASDAQ:APVO opened at $1.62 on Friday. Aptevo Therapeutics has a fifty-two week low of $1.37 and a fifty-two week high of $29.70. The business has a 50-day moving average of $2.18 and a two-hundred day moving average of $3.77. The stock has a market capitalization of $2.93 million, a P/E ratio of -0.03 and a beta of 1.67.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($5.31) EPS for the quarter, beating analysts’ consensus estimates of ($6.02) by $0.71. As a group, research analysts expect that Aptevo Therapeutics will post -17.04 EPS for the current fiscal year.
About Aptevo Therapeutics
Aptevo Therapeutics Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to harness the immune system by directing immune cells toward specific disease-associated targets.
Aptevo’s pipeline is built primarily around its proprietary ADAPTIR bispecific antibody technology, which is intended to create therapeutic antibodies capable of binding to two different targets.
See Also
- Five stocks we like better than Aptevo Therapeutics
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
